Patents by Inventor Judit Erchegyi
Judit Erchegyi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8691761Abstract: The invention is directed to somatostatin analogs which are receptor antagonists of the somatostatin receptor, including receptor-selective antagonists, especially sst2-selective antagonists. Related compounds and compositions are included, including antagonists complexed with or conjugated to radioactive nuclides. The antagonists of the invention are useful in diagnosing and treating neoplastic and non-neoplastic mammalian diseases; such methods, and kits, are encompassed.Type: GrantFiled: April 16, 2008Date of Patent: April 8, 2014Inventors: Jean E. F. Rivier, Judit Erchegyi, Jean Claude Reubi, Helmut R. Maecke
-
Patent number: 8501687Abstract: SRIF peptide antagonists, which are selective for SSTR2 in contrast to the other cloned SRIF receptors and which bind with high affinity to the cloned human receptor SSTR2 but do not activate the receptor, have many useful functions. Because they do not bind with significant affinity to SSTR1, SSTR3, SSTR4 or SSTR5, their administration avoids potential undesirable side effects. By incorporating radioiodine or the like in these SSTR2-selective SRIF antagonists, a labeled compound useful in drug-screening methods is provided. Alternatively, for use in therapy, highly radioactive moieties can be N-terminally coupled, complexed or chelated thereto. Because they block the receptor function, they can be used therapeutically to block certain physiological effects which SSTR2 mediates.Type: GrantFiled: June 13, 2011Date of Patent: August 6, 2013Inventors: Jean E. F. Rivier, Judit Erchegyi, Jean Claude Reubi, Helmut R. Maecke
-
Publication number: 20110269683Abstract: SRIF peptide antagonists, which are selective for SSTR2 in contrast to the other cloned SRIF receptors and which bind with high affinity to the cloned human receptor SSTR2 but do not activate the receptor, have many useful functions. Because they do not bind with significant affinity to SSTR1, SSTR3, SSTR4 or SSTR5, their administration avoids potential undesirable side effects. By incorporating radioiodine or the like in these SSTR2-selective SRIF antagonists, a labeled compound useful in drug-screening methods is provided. Alternatively, for use in therapy, highly radioactive moieties can be N-terminally coupled, complexed or chelated thereto. Because they block the receptor function, they can be used therapeutically to block certain physiological effects which SSTR2 mediates.Type: ApplicationFiled: June 13, 2011Publication date: November 3, 2011Inventors: Jean E.F. RIVIER, Judit ERCHEGYI, Jean Claude REUBI, Helmut R. MAECKE
-
Patent number: 7960342Abstract: SRIF peptide antagonists, which are selective for SSTR2 in contrast to the other cloned SRIF receptors and which bind with high affinity to the cloned human receptor SSTR2 but do not activate the receptor, have many useful functions. Because they do not bind with significant affinity to SSTR1, SSTR3, SSTR4 or SSTR5, their administration avoids potential undesirable side effects. Because they block the receptor function, they can be used therapeutically to block certain physiological effects which SSTR2 mediates. By incorporating radioiodine or the like in these SSTR2-selective SRIF antagonists, a labeled compound useful in drug-screening methods is provided. Alternatively, for use in therapy, highly radioactive moieties can be N-terminally coupled, complexed or chelated thereto.Type: GrantFiled: October 15, 2007Date of Patent: June 14, 2011Assignees: The Salk Institute for Biological Studies, Universitat Bern, University Hospital BaselInventors: Jean E. F. Rivier, Judit Erchegyi, Jean Claude Reubi, Helmut R. Maecke
-
Publication number: 20080299040Abstract: The invention is directed to somatostatin analogs which are receptor antagonists of the somatostatin receptor, including receptor-selective antagonists, especially sst2-selective antagonists. Related compounds and compositions are included, including antagonists complexed with or conjugated to radioactive nuclides. The antagonists of the invention are useful in diagnosing and treating neoplastic and non-neoplastic mammalian diseases; such methods, and kits, are encompassed.Type: ApplicationFiled: April 16, 2008Publication date: December 4, 2008Inventors: Jean E. F. RIVIER, Judit Erchegyi, Jean Claude Reubi, Helmut R. Maecke
-
Publication number: 20080260638Abstract: SRIF peptide antagonists, which are selective for SSTR2 in contrast to the other cloned SRIF receptors and which bind with high affinity to the cloned human receptor SSTR2 but do not activate the receptor, have many useful functions. Because they do not bind with significant affinity to SSTR1, SSTR3, SSTR4 or SSTR5, their administration avoids potential undesirable side effects. Because they block the receptor function, they can be used therapeutically to block certain physiological effects which SSTR2 mediates. By incorporating radioiodine or the like in these SSTR2-selective SRIF antagonists, a labeled compound useful in drug-screening methods is provided. Alternatively, for use in therapy, highly radioactive moieties can be N-terminally coupled, complexed or chelated thereto.Type: ApplicationFiled: October 15, 2007Publication date: October 23, 2008Applicant: The Salk Institute for Biological StudiesInventors: Jean E.F. Rivier, Judit Erchegyi, Jean Claude Reubi, Helmut R. Maecke
-
Patent number: 7238775Abstract: Analogs of SRIF which are selective for SSTR4 in contrast to the other cloned SRIF receptors are useful in determining tissue and cellular expression of the receptor SSTR4 and its biological role in regulating tumor growth. SRIF analog peptides, such as des-AA1,2,4,5,12,13[Ala7]-SRIF; des-AA1,2,4,5,12,13[Aph7]-SRIF, des-AA1,2,4,5,12,13[Aph7]Cbm-SRIF; des-AA1,2,4,5,12,13[Tyr2,Ala7]-Cbm-SRIF, and des-AA1,2,4,5,12,13[Tyr7,C?Me-L-2Nal8]-SRIF, and counterparts incorporating D-Cys3 and/or D-Trp8 and/or Ala11, bind with high affinity to the cloned human receptor SSTR4 and activate the receptor, but they do not bind with significant affinity to human SSTR1, SSTR2, SSTR3 or SSTR5. By incorporating an iodinated tyrosine in position-2 in these SSTR4-selective SRIF analogs, a labeled compound useful in drug-screening methods is provided. Alternatively, for use in therapy, cytotoxins or highly radioactive elements can be N-terminally coupled or complexed thereto.Type: GrantFiled: January 24, 2005Date of Patent: July 3, 2007Assignee: The Salk Institute for Biological StudiesInventors: Jean E. F. Rivier, Jean Claude Reubi, Judit Erchegyi, Roland Riek
-
Publication number: 20050245438Abstract: Analogs of SRIF which are selective for SSTR4 in contrast to the other cloned SRIF receptors are useful in determining tissue and cellular expression of the receptor SSTR4 and its biological role in regulating tumor growth. SRIF analog peptides, such as des-AA1,2,4,5,12,13[Ala7]-SRIF; des-AA1,2,4,5,12,13[Aph7]-SRIF, des-AA1,2,4,5,12,13[Aph7]Cbm-SRIF; des-AA1,2,4,5,12,13[Tyr2,Ala7]-Cbm-SRIF, and des-AA1,2,4,5,12,13[Tyr7,C?Me-L-2Nal8]-SRIF, and counterparts incorporating D-Cys3 and/or D-Trp8 and/or Ala11, bind with high affinity to the cloned human receptor SSTR4 and activate the receptor, but they do not bind with significant affinity to human SSTR1, SSTR2, SSTR3 or SSTR5. By incorporating an iodinated tyrosine in position-2 in these SSTR4-selective SRIF analogs, a labeled compound useful in drug-screening methods is provided. Alternatively, for use in therapy, cytotoxins or highly radioactive elements can be N-terminally coupled or complexed thereto.Type: ApplicationFiled: January 24, 2005Publication date: November 3, 2005Applicant: The Salk Institute for Biological StudiesInventors: Jean Rivier, Jean Reubi, Judit Erchegyi, Roland Riek
-
Patent number: 6689813Abstract: The invention relates to the use of peptide amides of formula (I) and phenylamino-oxoacetic acid derivatives of formula (II) as well as the salts of the above compounds as active substances for the preparation of pharmaceutical compositions possessing neurogenic and non-neurogenic antiinflammatory as well as analgetic effects.Type: GrantFiled: January 5, 2001Date of Patent: February 10, 2004Assignee: Biostatin Gyogyszerkutato-Fejleszto kft.Inventors: György Kéri, János Szolcsányi, Erika Pintér, Zsuzsanna Helyes, Judit Érchegyi, Anikó Horváth, Judith Horváth, István Teplán, László Õrfi
-
Publication number: 20010009899Abstract: The invention relates to the use of peptide amides of formula (I) 1Type: ApplicationFiled: January 5, 2001Publication date: July 26, 2001Inventors: Gyorgy Keri, Janos Szolcsanyi, Erika Pinter, Zsuzsanna Helyes, Judit Erchegyi, Aniko Horvath, Judit Horvath, Istvan Teplan, Laszlo Orfi
-
Patent number: 4948873Abstract: The present invention relates to novel gonadoliberine analogues of formula IGlp-His-Trp-Ser-X-W-Leu-Arg-Pro-Y (I)whereinX is Phe-, Tyr (3,5-.sup.3 H) or 3,5-dibromo-tyrosyl,W is Asu or Asp OR, wherein R is alkyl having 1 to 6 carbon atoms or phenyl or phenyl (alkyl having 1 to 4 carbon atoms), which latter two groups may optionally be substituted by nitro or one or more halogen atoms, andY is glycinamide, aza-glycinamide or alkylamino having 1 to 4 carbon atoms,and acid-addition salts thereof, processes for preparing the same and pharmaceutical compositions comprising the same.The novel compounds have an influence on the sexual processes.Type: GrantFiled: October 21, 1986Date of Patent: August 14, 1990Assignee: Richter Gedeon Vegyeszeti GyarInventors: Janos Seprodi, Istvan Teplan, Istvan Schon, Judit Erchegyi, Zsolt Vadasz, Olga N. nee Kuprina, Tamas Szirtes, Andras Selmezci, Bela Kanyicska
-
Patent number: 4751215Abstract: The invention relates to a process for increasing the sexual activity of birds and useful domestic mammals and for preparing spermatozoa suitable to their propagation. The process of the invention comprises treating sexually mature male birds or useful domestic mammals at least twice and at most four times with 0.1 to 5 .mu.g/kg of body weight of a compound of the general formula (I),Glp-His-Trp-Ser-Tyr-X.sub.1 -Leu-Arg-Pro-X.sub.4 (I)whereinX.sub.1 stands for a glycyl group, a natural or synthetic aminoacid or aminoacid derivative of D configuration, an -Asp-Q group of L configuration, wherein Q is attached to the .alpha.-carbonyl moiety of the aspartyl group and represents a C.sub.1-5 alkylamide, an arylamide, a C.sub.1-4 alkoxy or a benzyloxy group; andX.sub.4 stands for a glycylamide or a C.sub.1-4 alkylamide group,while keeping a pause of at least 30 hours and at most 72 hours between the consecutive treatments.Type: GrantFiled: April 15, 1986Date of Patent: June 14, 1988Assignee: INNOFINANCE Altalanos Innovacios PenzintezetInventors: Janos Seprodi, Zsolt Vadasz, Peter Peczely, Istvan Teplan, Judit Erchegyi, Tibor Muray, Istvan Gyorvari
-
Patent number: 4552864Abstract: The invention relates to new gonadoliberin derivatives of the formula (I)Glp-His-Trp-Ser-Tyr-X-Leu-Arg-Pro-Y, (I)whereinY represents a glycine-amide group or an -NH-alkyl group having 1 to 4 carbon atoms in the alkyl moiety,X stands for a D-thyroxyl, D-thyronyl or D-4-chlorophenylalanyl group,and acid addition salts and metal complexes thereof.The new nona- and decapeptide derivatives have an excellent luteinizing and folliculus stimulating hormone releasing activity, and they can therefore be used as active ingredients in pharmaceutical compositions for human or veterinary application.Type: GrantFiled: May 4, 1984Date of Patent: November 12, 1985Assignee: Reanal FinomvegyszergyarInventors: Ferenc Antoni, Judit Erchegyi, Aniko Horvath, Gyorgi Keri, Imre Mezo, Karoly Nikolics, Janos Seprodi, Andras Szell, Balazs Szoke, Istvan Teplan